Synteract focusing on specific therapeutic areas as it eyes market growth

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/showcake)
(Image: iStock/showcake)
The contract research organization (CRO) Synteract today announced the creation of “therapeutic centers of development” as it looks to deepen its footprint in the mid-size CRO market space.

According to the company, the centers of development will include oncology – especially immunotherapy studies – pediatrics, neuro-degenerative disorders, as well as rare and orphan diseases.

"Our centers of therapeutic development are areas of specific focus where we have a lot of experience,"​ Synteract CEO Steve Powell told us. 

The CRO will continue to support other therapeutic areas where clients have needs, he explained; "However, by more clearly defining our areas of ​specialization we have an opportunity to make it easier to answer 'Why Synteract?'"

Echoing this sentiment in the press release, chief commercial officer Jack Shannon said that by “more clearly delineating”​ the company’s attention on “these growing development areas”​ it will have “a real opportunity”​ to expand its presence in the mid-market space​.

The new position was created in collaboration with its customers and internal teams, according to the company. 

Related news

Show more

Related products

show more

QPS: Global Custom-Built Research Services

QPS: Global Custom-Built Research Services

QPS | 16-Dec-2019 | Product Brochure

Performing complex studies in special populations with remarkable agility. Clinical research just got better with QPS’ Custom-Built Research Services....

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us

Products

View more

Webinars